ProCE Banner Activity

CME

CCO Conference Highlights of AACR 2018

Slideset Download
Conference Coverage
Slideset
In this CME-certified downloadable slideset, Matthew Gubens, MD, MS; Mark E. Robson, MD; and Jeffrey S. Weber, MD, PhD, provide expert analysis on key studies from the 2018 AACR annual meeting in lung cancer, breast cancer, and melanoma, respectively.

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: May 29, 2018

Expiration: May 28, 2019

No longer available for credit.

Share

Faculty

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Mark E. Robson

Mark E. Robson, MD

Chief, Breast Medicine Service
Attending Physician
Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Jeffrey S. Weber

Jeffrey S. Weber, MD, PhD

Senior Member and Director
Comprehensive Melanoma Research Center
H. Lee Moffitt Cancer Center
Tampa, Florida

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

AstraZeneca Pharmaceuticals

Merck Oncology

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with cancer
  • Identify subpopulations of patients with cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers 
  • Discuss new data on novel agents and therapeutic approaches for patients with cancer
  • Consider how new trial findings might affect treatment of cancer clinical practice in the future

Disclosure

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Mersana Therapeutics, and Novartis and funds for research support paid to his institution from Merck and OncoMed.

Mark E. Robson, MD

Chief, Breast Medicine Service
Attending Physician
Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Mark E. Robson, MD, has disclosed that he has received consulting fees from AstraZeneca and McKesson; honorarium from AstraZeneca; and funds for research support paid to his institution from AbbVie, AstraZeneca, BioMarin, and Medivation.

Jeffrey S. Weber, MD, PhD

Senior Member and Director
Comprehensive Melanoma Research Center
H. Lee Moffitt Cancer Center
Tampa, Florida

Jeffrey S. Weber, MD, PhD, has disclosed that he has served on an advisory board for Merck and is named on a patent filed by Biodesix for a PD-1 biomarker.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 29, 2018, through May 28, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with cancer.